# Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting

> **NCT02690974** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 302 (actual)

## Conditions studied

- Hearth Failure With Reduced Ejection Fraction (HFrEF)

## Interventions

- **DRUG:** LCZ696 (sacubitril/valsartan)

## Key facts

- **NCT ID:** NCT02690974
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-08
- **Primary completion:** 2017-06-07
- **Final completion:** 2017-11-29
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2019-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02690974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02690974, "Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02690974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*